Janet Pope Janetbirdope
6 years 4 months ago
Young woman with SLE previously only arthritis, serology, Raynauds. Presented with fever, SOB during #pandemic Broad differential. Not always #COVID__19 @RheumNow https://t.co/jrmP3xHzcu
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
6 years 4 months ago
Phase 3 baricitinib trials (2890 pts) there were 215 prior/occult HBV infection (HbcAb+) and 8 (3.7%) had a positive HBV DNA+ (≥29 IU/mL). Four met the definition of reactivation and 3 required antiviral therapy = check HBV serologies with JAK inhib use https://t.co/9xGIu5hzNh
Dr. John Cush RheumNow
6 years 4 months ago
TNR Grand Rounds on "Cytokine Storm Syndromes" features a lecture and Q&A with Dr. Randy Cron - watch it here>> https://t.co/1CZ1YOY5W3 or listen on iTunes>> https://t.co/FHJv01AAbC or SoundCloud Podcast>> https://t.co/G0EuWMGTdW https://t.co/z57pBUhAKn
Dr. John Cush RheumNow
6 years 4 months ago
UPI quotes Dr. Tony Fauci stating (about hydroxychloroquine) "The scientific data is really quite evident now about the lack of efficacy". Yesterday France and other countries have banned the use of HCQ to treat COVID. https://t.co/G0EuWMGTdW
Dr. John Cush RheumNow
6 years 4 months ago
Great NY Times article on 30+ years of an adversarial friendship between Dr. Tony Fauci and AIDS activist Larry Kramer (who recently passed away). Keen that adversaries can still be on the same side, pushing for change differently https://t.co/lnfk6fXfF2
The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.
Dr. John Cush RheumNow
6 years 4 months ago
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers. https://t.co/JIb4FtiOQG
Dr. John Cush RheumNow
6 years 4 months ago
NEJM reports no difference between 5d and 10d course of Remdesivir in severe Covid-19 not requiring mechanical ventilation; but this trial did not include a placebo control https://t.co/mxAR2qQzPa
Dr. John Cush RheumNow
6 years 4 months ago
CORRONA registry compared Triple DMARD (MSH) to TNF/MTX Rx; MSH is infrequently used; Triple DMARD pts were older, longer Dz duration, less Dz activity, more CA & comorbidities. Comparatively MSH had more Discontinuations & less likely to get to LDAS https://t.co/WSHgzrfcIn
This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The program was moderated by Dr. Jack Cush.
Dr Philip Robinson philipcrobinson
6 years 4 months ago
Case-control study of risk factors for [rheumatic use] hydroxychloroquine retinopathy: cumulative dose, duration of intake, creatinine clearance and geographical origin sign^ in multivariate analysis, what is driving the geo finding? genetics? https://t.co/2NGaZiqpsc @RheumJnl
The Lancet Rheumatology TheLancetRheum
6 years 4 months ago
NEW RESEARCH: Repeat ANA testing after a negative result has low utility and results in high cost https://t.co/Zfc2vqRue1 #LancetRheumatology https://t.co/N9iHfdNYix
Jeff Sparks jeffsparks
6 years 4 months ago
Proud of this amazing collaboration with
@zach_wallace_md: 52 rheumatic cases vs. 104 non-rheumatic comparators, all infected with COVID-19. Rheum cases had 3-fold risk of mechanical ventilation
@BrighamResearch @MGHMedicine
https://t.co/nBXe78i4JU
